• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

VDAART RCT Results: Does Vitamin D Supplementation During Pregnancy Reduce Asthma Incidence in Children at 6 Years of Age?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Higher maternal vitamin D levels might be linked to a lower risk of asthma in children
    • The Vitamin D Antenatal Asthma Reduction Trial (VDAART) found that vitamin D supplementation is associated with a reduction in asthma and recurrent wheeze in 3-year-old children
  • Litonjua et al. (N Engl J Med, 2020) performed a 6-year follow-up on VDAART participants

METHODS:

  • Randomized, double-blind, placebo-controlled trial
    • VDAART Follow-up
  • Participants
    • Mothers, and offspring
    • Follow-up through offspring’s 6th birthday
  • Interventions
    • Vitamin D group: Mothers received 4000 IU plus multivitamin with 400 IU of vitamin D3 daily during pregnancy
    • Control group: Mothers received multivitamin with 400 IU of vitamin D3 daily during pregnancy
  • Primary outcome
    • Extension of original trial (at 6 years): Asthma | Recurrent wheeze | Both outcomes
  • Study design and data analysis
    • Investigators remained unaware of the treatment assignments
    • Time-to-event methods were used to compare the treatment groups with respect to time to the onset of asthma or recurrent wheeze
    • Multivariate methods were used to compare longitudinal measures of lung function between the treatment groups

RESULTS:

  • 806 children included
  • Maternal vitamin D supplementation level had no effect on
    • Primary outcome: Asthma and recurrent wheeze at 6 years
    • Prespecified secondary outcomes
    • Spirometric indexes

CONCLUSION:

  • While the original 3-year RCT demonstrated benefit in offspring, the 6-year follow-up failed to show that vitamin D supplementation during pregnancy could prevent asthma and recurrent wheeze

Learn More – Primary Sources:

Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Vitamin D Supplementation in Pregnancy Reduce the Risk of Enamel Defects in Children?
(Cochrane 2016) Vitamin D During Pregnancy and Adverse Pregnancy Outcomes
Does Vitamin D Intake Decrease the Risk for Gestational Diabetes Mellitus?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site